{"entity":{"id":"bh-30236","kind":"drug","name":"BH-30236","aka":[],"tldr":"BH-30236 is an experimental small molecule from BlossomHill Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes.","summary":"BH-30236 is a small molecule (oral, macrocyclic) from BlossomHill Therapeutics. An orally bioavailable macrocyclic inhibitor of the CDC-like kinase (CLK) family, designed to modulate aberrant alternative splicing that AML and higher-risk MDS cells exploit to develop resistance to venetoclax, FLT3 inhibitors and chemotherapy. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b first-in-human trial, recruiting (registry checked 3 Nov 2026); tested alone and with venetoclax. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"BlossomHill Therapeutics: bhtherapeutics.com","url":"https://www.bhtherapeutics.com/pipeline"},{"label":"BlossomHill Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06501196"},{"label":"ClinicalTrials.gov: trials of BH-30236","url":"https://clinicaltrials.gov/search?intr=BH-30236"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["aml","mds-higher-risk"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["blossomhill-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06501196"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BH-30236","modality":"Small molecule (oral, macrocyclic)","mechanism":"An orally bioavailable macrocyclic inhibitor of the CDC-like kinase (CLK) family, designed to modulate aberrant alternative splicing that AML and higher-risk MDS cells exploit to develop resistance to venetoclax, FLT3 inhibitors and chemotherapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bh-30236/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"}],"company":[{"id":"blossomhill-therapeutics","kind":"company","name":"BlossomHill Therapeutics","route":"/companies/blossomhill-therapeutics/"}],"trial":[{"id":"nct06501196","kind":"trial","name":"A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome","route":"/trials/nct06501196/"}]}}